Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome |
| |
| Authors: | Mohamad Cherry Marylou Cardenas-Turanzas Hannah Pham Hagop Kantarjian Jorge Cortes Sherry Pierce Lingsha Zhou Srdan Verstovsek |
| |
| Affiliation: | 1. Department of Hematology and Oncology, The University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA;2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3. Texas Tech University, Lubbock, TX, USA |
| |
| Abstract: | The clinical relevance of prior malignancy (PM) in patients with essential thrombocythemia (ET) and polycythemia vera (PV) is largely unknown. We retrospectively evaluated 437 patients (ET, n = 263; PV, n = 174) treated at MD Anderson between 1960 and 2010. Forty-four patients had PM (ET, 10%; PV, 11%), with median time to diagnosis of 66 months. PM was not associated with abnormal cytogenetics, JAK2-mutation frequency, blood-cell counts or progression to acute leukemia or myelofibrosis. In multivariate analysis, only older age and high LDH levels were associated with worse OS. In conclusion, PM does not predict worse outcomes for patients with ET and PV. |
| |
| Keywords: | Myeloproliferative disorders Polycythemia vera Essential thrombocythemia Prior malignancy Transformation to acute leukemia Transformation to myelofibrosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
